Who to call at Sonnet BioTherapeutics Holdings, and when
Fundz watches for the moments Sonnet BioTherapeutics Holdings starts buying, and tells you who to reach.
- An alert the day Sonnet BioTherapeutics Holdings raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Sonnet BioTherapeutics Holdings, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Sonnet BioTherapeutics Holdings. With Fundz connected, it knows.
Sonnet BioTherapeutics Enters Master Clinical Collaboration Agreement with Sarcoma Oncology Center for the Development of SON-1210 in Pancreatic Cancer Treatment
Contract Type
agreement
PrincetonBiotechnologyHealthcareDescription
Sonnet BioTherapeutics Holdings, Inc. has entered into a Master Clinical Collaboration Agreement with the Sarcoma Oncology Center to advance the development of SON-1210, a proprietary bifunctional version of human Interleukins 12 (IL-12) and 15 (IL-15), configured using Sonnet's Fully Human Albumin Binding (FHAB®) platform, in combination with chemotherapy for metastatic pancreatic cancer treatment.
Related People
Sonnet BioTherapeutics Holdings signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.